Horizon Discovery Group plc (LSE: HZD) ("Horizon"), the world leader in the application of gene editing technologies, including the provision of bioproduction cell lines, today announced it has entered into a research and development collaboration, and license agreement with AmplyCell S.A., to evaluate the impact of AmplyCell’s BOOST cell line optimisation technology on Horizon’s parental GS (glutamine synthetase) null CHO K1 cell line.
AmplyCell's Cell Fitness Technologies, which include BOOST, consist of a four-stage process to optimise cell lines in terms of stability and productivity. Cell lines can be stimulated using AmplyCell's Cell Fitness Technologies at any stage of cell line development or bioproduction (clone creation, RCB/DCB, MCB), without the need to change culture conditions.
Horizon is applying a disruptive business model alongside its expertise in genome editing to improve the manufacture of biotherapeutics, making its cutting-edge CHO cells available to companies of all sizes. Horizon’s CHO SOURCE platform comprises ...
